Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Living Cell Technologies Granted European Patent

Living Cell Technologies Limited

 
Living Cell Technologies Granted European Patent for Neurological Disease Product NTCELL

NTCELL targets neurological diseases such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis and Huntington’s disease and Stroke
Patent based on technology of implanting encapsulated porcine choroid plexus cells
Journal of Neural Engineering publishes LCT’s latest data on therapeutic benefit of choroid plexus cell implants

20 January 2010: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has been granted a European patent for the use of its product NTCELL in the treatment of degenerative neurological conditions such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis (MS), Huntington’s disease and Stroke.

LCT’s European patent is based on the technology of preparing NTCELL, which are encapsulated porcine cells of the choroid plexus of the brain. The cells release growth factors and neurotrophins, which are a range of agents that protect and maintain the health of brain cells. NTCELL was designed to protect brain cells from disease and injury and to enhance the natural repair mechanisms in the brain. NTCELL has the potential to restore neural cells and tissue.

The porcine choroid plexus cells are encapsulated in a seaweed-derived gel. The encapsulation protects the cells from rejection by the immune system allowing implantation without the need for toxic anti-rejection drugs.

Dr Paul Tan, Chief Executive Officer LCT said: “At a time when we are seeing regulatory approvals in Europe and the US for clinical trials with cell-based therapeutics in neurologic disorders, we can expect NTCELL to add significant value to LCT. The granting of this key patent for NTCELL coincides with the publication of LCT’s most recent data on cell therapy for neurological diseases in a leading peer review journal.”

The December 2009 issue of the Journal of Neural Engineering published LCT’s paper titled “Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma”, which shows that long-lasting therapeutic implants of NTCELL may be used to treat brain disease. The new experimental data indicates that the choroid plexus cells release neuroprotective agents including antioxidants and growth supporting factors. The implanted cells were still alive when retrieved 6 months after implantation into the brain in animals. This publication adds to LCT’s previously published and presented data on the beneficial effects of NTCELL implants in animal models of Parkinson’s disease, Huntington’s disease, stroke and hearing loss caused by degeneration of the auditory nerve.

 

-Ends-

 

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Media: Julian Wilcox Leaves Māori TV

Māori Television has confirmed the resignation of Head of News and Production Julian Wilcox. Mr Maxwell acknowledged Mr Wilcox’s significant contribution to Māori Television since joining the organisation in 2004. More>>

ALSO:

Genetics: New Heat Tolerant Cow Developed

Hamilton, New Zealand-based Dairy Solutionz Ltd has led an expert genetics team to develop a new dairy cow breed conditioned to thrive in lower elevation tropical climates and achieve high milk production under heat stress. More>>

Fractals: Thousands More Business Cards Needed To Build Giant Sponge

New Zealand is taking part in a global event this weekend to build a Menger Sponge using 15 million business cards but local organisers say they are thousands of business cards short. More>>

Scoop Business: NZ Net Migration Rises To Annual Record In September

New Zealand’s annual net migration rose to a record in September, beating government forecasts, as the inflow was spurred by student arrivals from India and Kiwis returning home from Australia. More>>

ALSO:

Scoop Business: Fletcher To Close Its Christchurch Insulation Plant, Cut 29 Jobs

Fletcher Building, New Zealand’s largest listed company, will close its Christchurch insulation factory, as it consolidates its Tasman Insulations operations in a “highly competitive market”. More>>

ALSO:

Scoop Business: Novartis Adds Nine New Treatments Under Pharmac Deal

Novartis New Zealand, the local unit of the global pharmaceuticals firm, has added nine new treatments in a far-ranging agreement with government drug buying agency, Pharmac. More>>

ALSO:

Crown Accounts: English Wary On Tax Take, Could Threaten Surplus

Finance Minister Bill English is warning the tax take may come in below forecast in the current financial year, as figures released today confirm it was short by nearly $1 billion in the year to June 30 and English warned of the potential impact of slumping receipts from agricultural exports. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand

Mosh Social Media
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news